Development Pipeline

Neoneuron is pursuing several neural cell products for the potential treatment of Parkinson’s disease, acute ischemic stroke, traumatic brain injury, and Alzheimer disease and related dementia.

Our lead candidate drug product is an allogeneic cellular therapy product NNDA001, for treating motor and non-motor problems caused by Parkinson’s disease.  We invented an MRI-compatible canula for intra-operative MRI-guided injection system for accurate, safe and effective administration of the drug product into brain areas undergoing neurodegeneration.